HORMONE RELATED MALIGNANCIES PROGRAM

描述：(申请人的描述)与荷尔蒙相关的目标 恶性肿瘤计划旨在降低癌症的发病率和死亡率 通过改善生殖道和内分泌系统的其他肿瘤 诊断、预防和治疗。这些目标是通过促进 基础、临床和人口科学家之间的研究合作， 以及不同研究学科的科学家之间的关系。程序性的 促进互动的活动包括每周一次的系列研究研讨会； 每周乳腺癌、前列腺癌和妇癌临床会议；年度 小型研讨会；每半年举行一次焦点小组会议。主实验室 该计划的研究主题是核和其他激素的研究 受体和细胞周期信号转导通路作为治疗靶点 以及动物模型中的肿瘤发展研究。主要临床活动 方案中有大剂量化疗的乳腺癌患者 造血干细胞支持，乳腺癌和前列腺癌的筛查研究 癌症，前列腺癌和妇科癌症的治疗研究。数量 自那以来，研究者发起的试验和这些试验的应计费用有所增加 最后一篇评论。这个计划是在融合了以前的基础科学的基础上发展起来的 荷尔蒙与癌症项目，乳腺癌和癌症临床项目 该病的重点人群为前列腺癌和妇科癌症。迪恩博士 爱德华兹，前乳腺癌项目的联合负责人，成为了 1999年担任项目负责人。他得到了工作人员调查人员加里·米勒的协助， 博士和伊丽莎白·J·什波尔医学博士。每个病区(乳腺癌、 前列腺癌、妇科癌症和内分泌癌)继续存在 除了合并后的每周临床会议外，还将每周单独召开临床会议 科学研讨会系列。来自四个重点领域的成员分别选择 这些研讨会的发言者和主题以及小型研讨会。34岁的 常规计划成员和7名同事来自七个部门，他们有 每年超过600万美元的直接成本研究和培训支持， 包括来自NCI的200多万美元和来自癌症的300多万美元 经纪公司。一项关于乳腺癌的联合培训赠款已由 计划成员(D.Edwards，PI)。未来的计划包括增加临床 乳腺癌和前列腺癌的招聘，所有领域的基本招聘， 提交联合计划项目和孢子申请。

Description: (Applicant's Description) The goal of the Hormone Related Malignancies Program is to lower the incidence and mortality rates of cancers of the reproductive tract and other tumors of the endocrine system by improved diagnosis, prevention, and therapy. These goals are achieved by facilitating research collaborations between basic, clinical, and population scientists, and between scientists with different research disciplines. Programmatic activities to stimulate interactions include a weekly research seminar series; weekly breast, prostate, and Gyn cancer clinical conferences; annual minisymposium; and semi-annual focus group meetings. The main laboratory research themes of the Program are study of nuclear and other hormone receptors and cell-cycle signal transduction pathways as therapeutic targets and tumor development studies in animal models. The main clinical activities of the program are high-dose chemotherapy of breast cancer patients with hematopoietic stem cell support, screening studies in both breast and prostate cancer, and prostate and Gyn cancer therapeutic studies. The number of investigator initiated trials and accrual to these trials have increased since the last review. This program evolved by merging the former basic science program, Hormones and Cancer, with the clinical program in Breast Cancer and the disease focus groups in prostate cancer and gynecologic cancers. Dr. Dean Edwards, former co-leader of the Breast Cancer program, became the overall program leader in 1999. He is assisted by staff investigators Gary Miller, MD, PhD, and Elizabeth J. Shpall, MD. Each of the disease areas (Breast Cancer, Prostate Cancer, Gyn Cancers, and Endocrine Cancers) continues to hold separate weekly clinical conferences in addition to the combined weekly scientific seminar series. Members from each of the four focus areas select the speakers and topics for these seminars as well as the minisymposia. The 34 regular program members and 7 associates come from seven departments and have more than $6 million in annual direct cost research and training support, including more than $2 million from the NCI and $3 million from cancer agencies. A joint training grant in breast cancer has been submitted by program members (D. Edwards, PI). Future plans include additional clinical recruitments in breast and prostate cancers, basic recruitments in all areas, submission of joint program projects, and a SPORE application.